Getting a novel drug to market is the endgame for many in biopharma but moving through the clinic without attracting the interest of a larger developer can be considered a slur. Figuring out whether these unencumbered projects are rare gems or fools’ gold is a major challenge, for both investors and pipeline-hungry partners.
Unpartnered Assets: On The Shelf Or Hidden Treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
